Peer-influenced content. Sources you trust. No registration required. This is HCN.
This study involved 566 men and women between the ages of 28 and 97 years, who were patients in a preventive cardiology practice. The PULS Cardiac Test measures multiple protein biomarkers, including hepatocyte growth factor, soluble Fas, and IL-16, and uses the results to calculate a five-year risk score for new ACS. All factors more than doubled their prior above the norm level. The 5-year ACS PULS risk score more than doubled as a result.
Cardiology November 30th 2021
Journal of Clinical Oncology
It was time for a change in neuroblastoma treatment planning, and this Original Report from the Journal of Clinical Oncology validates a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) while incorporating segmental chromosome aberrations (SCA) as an additional genomic biomarker.
Internal Medicine August 9th 2021
From the pages of Blood Advances comes this Clinical Trials & Observations piece discussing the IDEAL trial. Backed by visual abstracts, tables, and charts supporting the data, the article explores two key points in augmenting chemotherapy efficacy: caloric restriction and using insulin and adiponectin as potential biomarkers of B-ALL chemosensitivity.
Hematology April 27th 2021
In this MedPage Today interview with Jason Karlawish, MD, co-director of the Penn Memory Center at the University of Pennsylvania in Philadelphia and author of the new book, The Problem of Alzheimer’s: How Science, Culture, and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It, the biomarker “revolution” is discussed, along with the discovery of the idea of mild cognitive impairment.
Geriatrics April 14th 2021